MarketPulse

manufacturing issues

28 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Atara Biotherapeutics Faces Class Action Over FDA Approval Claims

Class action lawsuit filed against Atara Biotherapeutics alleges false statements about FDA approval prospects. Investors must seek lead plaintiff status by May 22, 2026.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Atara Biotherapeutics Hit With Securities Lawsuit Over Manufacturing, Study Claims

Rosen Law Firm urges $ATRA investors to meet May 22, 2026 deadline in securities lawsuit alleging false statements about manufacturing and clinical trial deficiencies.
ATRAsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Atara Biotherapeutics Faces Class Action Over Alleged Misstatements on Drug Candidate

Class action lawsuit filed against $ATARA alleging securities fraud over false statements regarding manufacturing issues and ALLELE study deficiencies affecting tabelecleucel approval prospects.
AQSTSLNOATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Atara Biotherapeutics Hit With Securities Fraud Class Action Over Failed Drug Approval

Pomerantz Law Firm files class action against $ATRA over alleged misstatements regarding tabelecleucel's regulatory prospects, following FDA rejections and severe stock declines.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

Atara Biotherapeutics Faces Securities Fraud Suit Over Concealed FDA Obstacles

Class action lawsuit alleges $ATRA misrepresented manufacturing issues and clinical trial deficiencies for tabelecleucel, obscuring FDA approval challenges between May 2024 and January 2026.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Atara Biotherapeutics Hit With Class Action Over Misleading Manufacturing Claims

Bronstein, Gewirtz & Grossman files class action against $ATAR, alleging executives misled investors about manufacturing issues and FDA approval prospects for tabelecleucel.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ATRA Stock Investors Face Critical Deadline in Securities Class Action Over FDA Setback

Securities lawsuit filed against Atara Biotherapeutics over alleged misstatements regarding tabelecleucel manufacturing and failed ALLELE study. Lead plaintiff deadline May 22, 2026.
ATRAinvestor lossessecurities class action
BenzingaBenzinga··Vandana Singh

AbbVie's TrenibotE Setback Raises Manufacturing Questions Amid $1.4B Plant Investment

AbbVie received FDA rejection for wrinkle drug TrenibotE over manufacturing issues, though safety and efficacy cleared. Company plans response within months.
ABBVFDA rejectionComplete Response Letter
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

ATRA Faces Securities Fraud Lawsuit Over Misleading FDA Prospects and Manufacturing Claims

Class action lawsuit filed against Atara Biotherapeutics alleging false statements about manufacturing issues and regulatory prospects for tabelecleucel.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Glancy Prongay Wolke & Rotter Llp

ATRA Stock Crashes 97% Total as FDA Rejects Cancer Drug Twice; Class Action Lawsuit Looms

Atara Biotherapeutics stock collapsed 97% across two FDA rejections for tabelecleucel. Class action deadline: May 22, 2026.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Atara Biotherapeutics Faces Class Action Over Alleged Misstatements on Drug Approval

Class action lawsuit filed against $ATARA alleging executives misled investors about manufacturing issues and study deficiencies affecting tabelecleucel FDA approval prospects.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

ATRA Faces Securities Lawsuit Over Tabelecleucel Setbacks; Lead Plaintiff Deadline Looms

Atara Biotherapeutics faces class action lawsuit alleging false statements about manufacturing and ALLELE study deficiencies. Lead plaintiff deadline set for May 22, 2026.
ATRAsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··The Gross Law Firm

ATRA Faces Securities Class Action Over FDA Drug Approval Setbacks

Shareholders sue Atara Biotherapeutics for allegedly misleading statements on manufacturing issues and failed ALLELE study data affecting tabelecleucel approval prospects.
ATRAshareholder lawsuitsecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Securities Lawsuit Targets Atara Biotherapeutics Over Tabelecleucel Disclosure Failures

Securities lawsuit alleges Atara Biotherapeutics concealed manufacturing issues and clinical study deficiencies for tabelecleucel. Investors with $100K+ losses must act before May 22, 2026 deadline.
ATRAinvestor lossessecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Hagens Berman

Eos Energy Faces Class Action Over Scaling Claims as Stock Crashes 39%

Eos Energy ($EOSE) faces securities lawsuit over false scaling statements and undisclosed manufacturing problems. Stock plunged 39% after missing revenue targets.
EOSEsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Atara Biotherapeutics Faces Securities Class Action Over FDA Study Misstatements

Securities lawsuit filed against $ATRA over alleged false statements on manufacturing issues and ALLELE study deficiencies affecting tabelecleucel approval prospects.
ATRAsecurities class actionmisleading statements
GlobeNewswire Inc.GlobeNewswire Inc.··Kirby Mcinerney Llp

Atara Biotherapeutics Faces Securities Fraud Class Action Over Failed Drug Candidate

Class action lawsuit filed against $ATRA over alleged misstatements on tabelecleucel prospects. FDA rejected drug twice; stock crashed 40-57% post-announcements.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Levi & Korsinsky, Llp

ATRA Hit With Securities Fraud Suit Over Manufacturing Issues, Regulatory Misstatements

Atara Biotherapeutics faces securities fraud class action for allegedly misrepresenting manufacturing capabilities and overstating regulatory prospects for tabelecleucel between May 2024 and January 2026.
CWHINOATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Bronstein, Gewirtz & Grossman Llc

Class Action Alleges Atara Biotherapeutics Concealed Manufacturing and Trial Defects

Class action lawsuit filed against Atara Biotherapeutics for allegedly misrepresenting manufacturing issues and ALLELE study deficiencies affecting tabelecleucel approval prospects.
ATRAsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Atara Biotherapeutics Faces Securities Lawsuit Over Tabelecleucel Manufacturing Claims

Rosen Law Firm urges $ATRA investors to join class action alleging false statements about manufacturing and regulatory prospects for tabelecleucel drug.
ATRAsecurities class actionlead plaintiff deadline